The UK MHRA (Medicines and Healthcare products Regulatory Agency) has now granted the authorization to the Evusheld of AstraZeneca for the pre-exposure prophylaxis (PrEP) against the novel corona virus, and the Evusheld has been a cocktail of the two monoclonal long-acting antibodies, along with the cilgavimab and tixagevimab.
The company ‘AstraZeneca’ has now licensed the antibodies that has been discovered by Vanderbilt University in the month of June 2020, and the antibody combination mainly acts by attaching to the novel corona virus spike protein, and this approach has also been hindering the entry of the virus into the human cells.
According to the approval of UK MHRA, the Evusheld has been indicating for the usage of the vaccine in the adults, who are not presently infected with the novel corona virus and the people, who might not have any sufficient response to the vaccine, and the Tixagevimab and the cilgavimab is going to be administered as a separate sequential intramuscular (IM) doses.
According to the initial results from the ongoing Phase 3 trial, that has demonstrated for offering a statistically significant decrease in the risk of the symptomatic corona virus development against the placebo along with meeting the primary endpoint. The data has also showed that, the treatment has also been offering the protection from the novel corona virus that has been lasted for at least six months and the Evusheld had been demonstrated for being tolerated.
